Skip to main content
Premium Trial:

Request an Annual Quote

Evotec, Celmatix Partner on Women's Reproductive Health Drug Discovery

NEW YORK — Evotec and Celmatix said today that they have formed a drug-discovery partnership focused on prevalent but underserved women's reproductive health conditions including polycystic ovary syndrome, endometriosis, and infertility.

Under the terms of the alliance, Hamburg, Germany-based Evotec will be responsible for medicinal chemistry and in vitro and in vivo pharmacology activities. Celmatix — which recently launched a division to discover therapeutics for women's health indications including reproductive disorders — will contribute to drug-discovery efforts using its Reproductive Atlas platform, which combines biological annotations from peer-reviewed literature with genomic data associated with lifestyle, diet, environment, and reproductive outcomes.

Additional terms were not disclosed.

"Through combining our vast datasets and deep expertise in women's health with Evotec's proven experience in therapeutic discovery, we are poised to catalyse real change and finally provide women therapies they deserve," Piraye Yurttas Beim, founder and CEO of New York City-based Celmatix, said in a statement.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.